Medscape |
---|
FDA: No Excess Mortality Risk From Paclitaxel PAD Devices |
![]() The US Food and Drug Administration (FDA) has determined that paclitaxel-delivering stents and balloons for peripheral-artery interventions do not pose an excess mortality risk, the agency said today in a statement to healthcare providers. |
||
2023-07-11 Read more about this article in source |
-
The ‘Six Pillars of Brain Health’ offers a game plan to maintain cognitive function 04/25/2025
-
Avocados, cheese and nuts are high in calories but have big health benefits 04/25/2025
-
Perfecting the squat before trying a lunge can start you off on the right foot 04/25/2025